In a phase 1 trial, treatment with the antibody−drug conjugate DYP688, targeting PMEL and delivering a Gq/11 inhibitor, in patients with GNAQ/GNA11-mutant metastatic uveal melanoma or other GNAQ/GNA11-mutant melanomas, showed acceptable safety and encouraging preliminary efficacy, with supporting biomarker data for proof of mechanism.